Bozorgi v. Cassava Sciences — 5th Cir. (Aug 3, 2026)
The Fifth Circuit reviews certification of a securities-fraud class against Cassava Sciences and three executives. Investors say Cassava misled the market about simufilam, its experimental Alzheimer's drug. Their class depends on showing that public information was reflected in Cassava's stock price, so reliance can be presumed for all investors. The defendants say the volatile stock behaved like a meme stock, and they also challenge the class-wide damages method. A later settlement raises a separate question: whether this interlocutory appeal should continue.
Bozorgi v. Cassava Sciences (No. 25-50855) — U.S. Court of Appeals for the Fifth Circuit, argued August 3, 2026.
- 0:00Introduction
- 1:13Gregg Costa
- 17:56Joseph D. Daley